Everything below concerns lyophilized powder. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-11-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
=== Other tumors === In a few people, acromegaly is caused by tumors of the pancreas, lungs, and adrenal glands. These tumors also lead to an excess of GH, either because they produce GH themselves or, more frequently, because they produce GHRH (growth hormone-releasing hormone), the hormone that stimulates the pituitary to make GH. When these nonpituitary tumors are surgically removed, GH levels fall and the symptoms of acromegaly improve.
A Mesmerian Experiment (French: Le Baquet de Mesmer) is a 1905 French silent trick film by Georges Méliès. It was sold by Méliès's Star Film Company and is numbered 693–695 in its catalogues. Méliès appears in the film Doctor Mesmer. The film has few illusions, and is mainly a vehicle for its troupe of dancers, identified in Méliès's American film catalogue as the "Snow-drops" of London's Alhambra Theatre of Variety. The film's technical effects were carried out with pyrotechnics and substitution splices.
=== Occupational and habitation rehabilitation === Thirty-three of the 50 planned work-sheds for gas victims started. All except one was closed down by 1992. In 1986, the MP government invested in the Special Industrial Area Bhopal. One hundred and fifty-two of the planned 200 work sheds were built and in 2000, 16 were partially functioning. It was estimated that 50,000 persons need alternative jobs, and that less than 100 gas victims had found regular employment under the government's scheme. The government also planned 2,486 flats in two- and four-storey buildings in what is called the "widow's colony" outside Bhopal. The water did not reach the upper floors and it was not possible to keep cattle which was their primary occupation. Infrastructure like buses, schools, etc. were missing for at least a decade.
Sources: en.wikipedia.org
Nicergoline is an ergot alkaloid derivative that acts as a potent and selective α1A-adrenergic receptor antagonist. The IC50 of nicergoline in vitro has been reported to be 0.2 nM. The primary action of nicergoline is to increase arterial blood flow by vasodilation. Furthermore, it is known that nicergoline inhibits platelet aggregation. Studies have shown that nicergoline also increases nerve growth factor in the aged brain. In addition to the α1A-adrenergic receptor, nicergoline is an antagonist of the serotonin 5-HT1A receptor (IC50 = 6 nM) and shows moderate affinity for serotonin 5-HT2 and α2-adrenergic receptors and low affinity for the dopamine D1 and D2 and muscarinic acetylcholine M1 and M2 receptors.
7 April Astronomers report the discovery of HD1, considered to be the earliest and most distant known galaxy yet identified in the observable universe, located only about 330 million years after the Big Bang 13.8 billion years ago, a light-travel distance of 13.5 billion light-years from Earth, and, due to the expansion of the universe, a present proper distance of 33.4 billion light-years. Physicists from the Collider Detector at Fermilab determine the mass of the W boson with a precision of 0.01%. The result hints at a flaw in the Standard Model. A trial of estimated financial energy cost of refrigerators alongside EU energy-efficiency class (EEEC) labels online finds that the approach of labels involves a trade-off between financial considerations and higher cost requirements in effort or time for the product-selection from the many available options which are often unlabelled and don't have any EEEC-requirement for being bought, used or sold within the EU. 8 April Bioresearchers demonstrate an in vitro method (MPTR) for rejuvenation (including the transcriptome and epigenome) reprogramming in which fibroblast skin cells temporarily lose their cell identity. Researchers show air pollution in fast-growing tropical cities caused ~500,000 earlier deaths in 2018 with a substantial recent and projected rise, proposing "regulatory action targeting emerging anthropogenic sources".
ESI interface for LC–MS systems was developed by Fenn and collaborators in 1988. This ion source/ interface can be used for the analysis of moderately polar and even very polar molecules (such as metabolites, xenobiotics, peptides, nucleotides, and polysaccharides). The liquid eluate coming out of the LC column is directed into a metal capillary kept at 3 to 5 kV and is nebulized by a high-velocity coaxial flow of gas at the tip of the capillary, creating a fine spray of charged droplets in front of the entrance to the vacuum chamber. To avoid contamination of the vacuum system by buffers and salts, this capillary is usually perpendicularly located at the inlet of the MS system, in some cases with a counter-current of dry nitrogen in front of the entrance through which ions are directed by the electric field. In some sources, rapid droplet evaporation and thus maximum ion emission is achieved by mixing an additional stream of hot gas with the spray plume in front of the vacuum entrance. In other sources, the droplets are drawn through a heated capillary tube as they enter the vacuum, promoting droplet evaporation and ion emission. These methods of increasing droplet evaporation now allow the use of liquid flow rates of 1–2 mL/min to be used while still achieving efficient ionisation and high sensitivity.
Sources: en.wikipedia.org
=== Antiquity === Ancient Babylonian texts describe symptoms resembling migraine, which were believed to be caused by supernatural forces and were treated using spiritual or religious practices. A description consistent with migraine is contained in the Ebers Papyrus, written around 1500 BCE in ancient Egypt. Trepanation, a surgical procedure involving drilling or scraping an opening into the skull, has been practiced since the Neolithic period, although there is little evidence that it was specifically used to treat headaches or migraine. During the Greco-Roman era, explanations for migraine shifted from supernatural beliefs to the theory of the four humors. Writings from the Hippocratic school of medicine described the visual aura that can precede headache and noted that vomiting could provide partial relief. Headaches were thought to result from an imbalance of these bodily fluids. A description by Aretaeus of Cappadocia classified headaches into cephalalgia, cephalea, and heterocrania, while Galen of Pergamon adapted this latter term to produce "hemicrania", from which the modern word migraine is derived. He proposed that the pain arose from the meninges and blood vessels of the head. The mystical visions described by Hildegard von Bingen as "reflections of the living light", have been interpreted by some scholars as being consistent with the visual aura experienced during migraine attacks.
=== Nutrient delivery system === Immunoliposomes can also be used as nutrient delivery systems to help stimulate brain activity. The effective transport of certain nutrients to the hypothalamus in order to regulate brain activity is currently a huge problem. The leptin gene is used to regulate feedback loops and send signals from the adipose tissue to the hypothalamus. Using this physiological function of leptin, immunoliposome nutrient delivery systems can be integrated into the body to help with nutrition transport to the brain as seen in Figure 5. Transferrin receptors have high expression at the BBB (blood brain barrier) and can be used as targets for immunoliposomes to transport p-glycoprotein substances.
==== Deuteron mass and radius ==== The deuterium nucleus is called a deuteron. It has a mass of 2.013553212544(15) Da (1875.61294500(58) MeV/c2). The charge radius of a deuteron is 2.12778(27)×10−15 m. Like the proton radius, measurements using muonic deuterium produce a smaller result: 2.12562(78) fm.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.